Follow-up data of 10 patients with b-cell non-hodgkin lymphoma with a cd20-negative phenotypic change after rituximab-containing therapy

American Journal of Surgical Pathology

Volumn 37, Issue 4, 2013, Pages 563-570

  Maeshima, Akiko M ^a   Taniguchi, Hirokazu ^a   Fukuhara, Suguru ^a   Morikawa, Noriyuki ^a   Munakata, Wataru ^a   Maruyama, Dai ^a   Kim, Sung Won ^a   Watanabe, Takashi ^a   Kobayashi, Yukio ^a   Tobinai, Kensei ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

B cell non Hodgkin lymphoma; CD20; follow up data; rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHENOTYPE;

EID: 84875227969     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182759008     Document Type: Article

References (32)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
2. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDECC2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
3. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
4. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15-24.
5. Maloney DG, Grillo-Lo pez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
6. Maloney DG, Grillo-Lo pez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
7. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998;9:527-534.
8. McLaughlin P, Grillo-Lo pez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
9. Meeker T, Lewder J, Cteary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312:1658-1665.
10. Kinoshita T, Nagi H, Murate T, et al. CD20-negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol. 1998;16:3916.
11. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611-615.
12. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol. 1999;106:571-572.
13. Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001;114:881-883.
14. Chu PG, Chen YY, Molina A, et al. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma. 2002;43:2335-2341.
15. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119:412-416.
16. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102:3514-3520.
17. Goteri G, Olivieri A, Ranaldi M, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients' outcome. Int J Immunopathol Pharmacol. 2006;19:421-431.
18. Seliem RM, Freeman JK, Steingart RH, et al. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006;14:18-23.
19. Alovaro-Naranjo TA, Jaen-Martinez JJ, Guma-Padro JG, et al. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol. 2003;82:585-588.
20. Woehrer S, Streubel B, Chott A, et al. Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma. 2005;46: 1645-1649.
21. Scaramucci L, Perrotti A, Niscola P, et al. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab. Leuk Lymphoma. 2007;48:1878-1880.
22. Maeshima AM, Taniguchi H, Nomoto J, et al. Histologic and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy. Cancer Sci. 2009;100:54-61.
23. Pijuan L, Vicioso L, Bellosillo B, et al. CD20-negative T-cell-rich Bcell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol. 2005;29:1399-1403.
24. Cragg MS, Bayne MC, Illidge TM, et al. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 2004;103:3989-3990.
25. Rawal YB, Nuovo GJ, Frambach GE, et al. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol. 2005;32:616-621.
26. Takei K, Yamazaki T, Sawada U, et al. Analysis of changes in CD20, CD55, and CD59 expression on established rituximabresistant B-lymphoma cell lines. Leuk Res. 2006;30:625-631.
27. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.
28. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximabcontaining chemotherapy. Int J Hematol. 2007;86:49-57.
29. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximabcontaining combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885-4893.
30. Miyoshi H, Arakawa F, Kimura Y, et al. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment. Cancer Sci. 2012;103: 1567-1573.
31. Jazirehi AR, Vega MI, Bonavida B. Development of rituximabresistant lymphoma clones with altered cell signaling and crossresistance to chemotherapy. Cancer Res. 2007;67:1270-1281.
32. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.